Allergan Restasis approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Allergan's Restasis (cyclosporine ophthalmic emulsion 0.5%) clears FDA Dec. 23 for treatment of keratoconjunctivitis sicca (chronic dry eyes) after a protracted review. The original Feb. 24, 1999 NDA was granted priority status, but review was complicated by a unanimous advisory committee vote against approval in July 1999 and three "approvable" letters. In the NDA's four studies comparing Restasis to vehicle in 1,200 patients, a statistically significant increase in Schirmer wetting at six months was seen in 15% of Restasis patients. The agent will be available in early Apri
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.